8/103 sources · 2 publishersUpdated Oct 8, 15:49 UTC
Summit Therapeutics partners with AstraZeneca and Daiichi Sankyo on Phase III ivonescimab/Datroway trial
Summit Therapeutics announced a clinical collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab together with the ADC Datroway. The partners will start with a Phase III study in first‑line triple‑negative breast cancer and will share trial costs, with AstraZeneca or Daiichi sponsoring. The agreement was disclosed on 2 Oct 2026.
Why it matters
Summit shares rose 1.5% in pre‑market trading following the announcement. Barclays lifted Summit’s price target to $20, suggesting analysts see potential upside from the collaboration.
Key facts
- 1The collaboration will begin with a Phase III trial in first‑line triple‑negative breast cancer. gurufocus.com
- 2Each company will contribute its therapy and share trial costs, with AstraZeneca or Daiichi Sankyo sponsoring the study. gurufocus.com
- 3Summit ended the second quarter with $690.7 million in cash and short‑term investments. tradingview.com
- 4Summit raised more than $68 million this quarter. tradingview.com
- 5Barclays raised Summit’s price target to $20 from $18. tradingview.com
- 6Summit shares were up 1.5% in pre‑market trading. tradingview.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.